fr 900482 has been researched along with Necrosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beckerbauer, L; Cullison, J; Reeves, R; Tepe, JJ; Williams, RM | 1 |
| Beckerbauer, L; Eastman, RA; Mixter, PF; Reeves, R; Tepe, JJ; Williams, RM | 1 |
2 other study(ies) available for fr 900482 and Necrosis
| Article | Year |
|---|---|
FR900482 class of anti-tumor drugs cross-links oncoprotein HMG I/Y to DNA in vivo.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Cell Division; Cross-Linking Reagents; DNA; DNA-Binding Proteins; High Mobility Group Proteins; Histocytochemistry; HMGA1a Protein; Humans; Jurkat Cells; Mitomycin; Models, Molecular; Molecular Sequence Data; Molecular Structure; Necrosis; Oncogene Proteins; Oxazines; Phosphoproteins; Precipitin Tests; Protein Structure, Tertiary; Substrate Specificity; Transcription Factors | 2000 |
Differential effects of FR900482 and FK317 on apoptosis, IL-2 gene expression, and induction of vascular leak syndrome.
Topics: Antineoplastic Agents; Apoptosis; Capillary Leak Syndrome; DNA; Humans; Interleukin-2; Jurkat Cells; Molecular Sequence Data; Necrosis; Oxazines; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Up-Regulation | 2002 |